Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Silexion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Silexion Therapeutics's regulatory disclosures and financial reporting.
Silexion Therapeutics Corp CSO and CDO Shirvan Mitchell reported an open-market sale of 22,818 Ordinary Shares on March 26, 2026 at $1.36 per share. According to the footnotes, this was a sale-to-cover transaction to pay tax liabilities from a fully vested restricted share unit grant received on February 20, 2026.
After the sale, Mitchell directly held 27,889 Ordinary Shares. He also held a stock option over 478 Ordinary Shares with an exercise price of $907.71 per share and an expiration date of June 7, 2032, adjusted to reflect prior reverse share splits.
Silexion Therapeutics Corp reported a boardroom change, noting that its Board of Directors removed Ilan Levin from his role as a director, effective immediately on March 25, 2026. The remaining board members acted unanimously by written determination under Article 28.7 of the company’s Amended and Restated Articles of Association.
Silexion Therapeutics Corp reports that the Israeli Ministry of Health has formally approved a Phase 2/3 clinical trial of its RNAi therapy SIL204 in locally advanced pancreatic cancer. SIL204 is designed to silence a broad range of KRAS mutations, which occur in over 90% of pancreatic cancers, and has shown significant anti-tumor activity in multiple preclinical models with supportive toxicology data. The company expects to begin the Phase 2/3 trial in the second quarter of 2026, subject to site activation and standard readiness steps, and plans additional regulatory filings in Germany by the end of the current quarter and across the European Union in early 2027.
Silexion Therapeutics Corp reconvened its extraordinary general meeting on March 23, 2026 after the prior session was adjourned for lack of quorum. Shareholders present represented approximately 36.6% of issued and outstanding ordinary shares, which became a valid quorum under the company’s articles after a half hour.
Shareholders voted on an Authorized Share Capital Increase Proposal and an Evergreen Increase Proposal. The authorized capital proposal received 461,249 votes (38.2%) in favor and 744,775 (61.8%) against, with 10,345 abstentions. The evergreen proposal received 486,671 votes (40.7%) in favor and 709,115 (59.3%) against, with 20,583 abstentions. Neither proposal achieved the required simple majority of votes cast by shareholders present, so both measures were rejected.
Silexion Therapeutics Corp files its annual report as a clinical‑stage biotech focused on RNA‑interference therapies for KRAS‑driven cancers, initially pancreatic cancer. Its lead candidate, SIL204, is an optimized siRNA designed to silence mutated KRAS and be used with standard chemotherapy.
The company plans an adaptive Phase 2/3 trial in locally advanced pancreatic cancer starting in the second quarter of 2026, with about 403 patients overall and an initial 15–21‑patient safety run‑in. Prior Phase 2 data with its first‑generation siRNA showed a non‑significant trend toward longer overall survival when added to chemotherapy.
Silexion discloses heavy reliance on external manufacturers, the need to raise substantial additional funding (including via an at‑the‑market program and warrant exercises), potential dilution from converting sponsor notes, and risks tied to operations in Israel and maintaining its Nasdaq listing. As of March 10, 2026, 3,330,785 ordinary shares were outstanding.
Noy Shlomo reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that Guangzhou Sino-Israel Biotech Fund (GIBF), an entity associated with director Noy Shlomo, was granted equity awards in connection with director services provided by GIBF’s CEO and Managing Partner, Avner Lushi. GIBF received fully vested restricted share units that were immediately settled into 9,091 ordinary shares, at a price of $0.00 per share. GIBF was also granted 10,685 stock options to purchase ordinary shares, with these options vesting in full on the one‑year anniversary of the board’s approval date and expiring on the ten‑year anniversary of that approval. The filing notes that Shlomo has shared voting and investment authority through his role as Chief Medical Officer of GIBF and disclaims beneficial ownership beyond any indirect pecuniary interest, and one line item is included only to show existing holdings with no new transaction.
Silexion Therapeutics Corp director Alon Ruth received new equity awards in the form of both shares and options. On February 20, 2026, Ruth was granted 9,091 Ordinary Shares at a price of $0.0000 per share, issued through fully vested restricted share units that were immediately settled into ordinary shares for his board service.
On the same date, he also received a grant of stock options covering 10,685 Ordinary Shares at an exercise price of $0.0000 per share, reflecting compensation for his role as a director. According to the filing, these options vest in full on the one-year anniversary of the grant approval date and expire on the ten-year anniversary of that approval date, providing a long-dated incentive tied to his continued board service. An additional row in the filing simply updates existing option holdings and does not reflect a new transaction.
Shirvan Mitchell reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp chief scientific and development officer Shirvan Mitchell received a grant of 49,726 fully vested restricted share units that were immediately settled into ordinary shares at no cost, for his services as an officer and approved by the board. Following this award, his direct holdings total 50,707 ordinary shares, and he also directly holds stock options covering 478 ordinary shares, which are reported here for informational purposes only. The share and option amounts reflect prior 1-for-9 and 1-for-15 reverse share splits effective in late 2024 and mid‑2025.
Silexion Therapeutics Corp reported that CFO and Secretary Hadar Mirit Horenshtein acquired 49,726 Ordinary Shares on account of a fully vested restricted share unit grant. The RSUs were immediately settled into ordinary shares as compensation for service as an officer, approved by the board of directors.
Following this grant, Horenshtein directly owns 50,146 Ordinary Shares of Silexion Therapeutics Corp.
Hadar Ilan reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp Chairman and CEO Hadar Ilan received a grant of 64,350 fully vested restricted share units that were immediately settled into ordinary shares at a price of $0.0000 per share, as compensation for officer services and approved by the board. Following this award, Ilan directly holds 65,471 ordinary shares. The filing also lists 956 stock options to buy ordinary shares for informational purposes only, with no new option transaction reported.